All Therapeutics articles – Page 2
-
NewsNovartis to site fifth radioligand therapy manufacturing facility in Texas
Investment to support production of radiopharmaceutical cancer therapies and forms part of Novartis’ planned $23 billion investment in its US capabilities.
-
NewsNovo Nordisk strikes $2.1bn oral obesity biologic deal with Vivtex
Drug delivery partnership to advance next-generation oral therapies and help Novo Nordisk expand its obesity and diabetes portfolio.
-
NewsGSK acquires TGF-beta protein firm 35Pharma for nearly $1bn
Acquisition will help GSK scale its pipeline for respiratory, immunology and inflammatory diseases.
-
NewsAbbVie invests $380m in Illinois to expand US API manufacturing
Decision forms part of the pharma company’s plan to commit $100 billion to its R&D capabilities in the US over the next decade.
-
ArticleApplying AI to enhance drug formulation and development
AI/ML is not replacing formulation scientists or process engineers; it is just amplifying their expertise.
-
NewsFDA drafts new ultra-rare disease therapy guidance
Agency’s planned framework is the first to support the approval process for new ultra-rare disease treatments.
-
NewsGilead adds to cell therapy portfolio with $8bn acquisition of Arcellx
Deal builds on the companies’ 2022 collaboration over CAR T therapy anito-cel.
-
NewsLilly's Omvoh demonstrates long-term potential in Crohn’s
New late-stage data shows the drug enabled the majority of IBD patients to stay steroid free over three years of Omvoh treatment.
-
NewsFDA policy sets new clinical trial requirements for drug approvals
The default standard would see US drug and biologic approvals require a single, robust pivotal study plus confirmatory evidence, instead of two trials.
-
NewsJohnson & Johnson invests $1bn in US cell therapy manufacturing
New Pennsylvania plant forms part of the pharma company’s $55 billion commitment to expand its US manufacturing footprint before the end of the decade.
-
NewsRecipharm sells manufacturing site to Scinai in biologics collaboration
Recipharm forms a long-term partnership with the Israeli biopharma and CDMO covering early development through to commercial supply.
-
NewsPfizer’s Braftovi improves progression-free survival in colorectal cancer
A triple therapy combination of the drug could offer a “potentially practice-changing treatment option”, according to new late-stage data.
-
NewsGSK wins dual EU approval for its ultra-long-acting biologic Exdensur
The European Commission’s decision covers the treatment’s use in severe asthma and chronic rhinosinusitis.
-
NewsOrsellinic acid produced in E. coli for first time
Study findings could provide an alternative production platform for rhododendron-derived drugs with potent anticancer and anti-HIV properties.
-
NewsSanofi’s Beyfortus shows infant benefit beyond first RSV season
The biologic enabled a significant reduction in RSV-related hospitalisations in infants through a second RSV season.
-
NewsNovartis bolsters the case for Vanrafia’s full approvals in IgA nephropathy
Phase III results will support the firm’s planned filings for traditional approvals later in 2026, following last year’s US and China accelerated approvals.
-
NewsAmgen wins new European approval for Uplizna in generalised myasthenia gravis
The EC decision clears a new first-in-class approach to manage the rare autoimmune condition.
-
NewsFormulation research offers step towards digital tablet design
Findings could lead to more robust tablet design and a minimising of the materials used, such as active pharmaceutical ingredients (APIs).
-
NewsSanofi selects Dr Belén Garijo as new CEO
The company veteran will return to lead the pharma firm, taking over from Paul Hudson.
-
ArticleAccelerating consistent, stable cell line development with targeted integration
Experts from WuXi Biologics explain how next-generation cell line development with targeted integration advances the field by enabling the production of clonal cell lines with predictable transgene copies at specific, predefined sites in the host genome.